Sandoz to strengthen Danish market position and Nordic operations with acquisition of danish Astra Zeneca's generics subsidiary
Strategic acquisition of Durascan makes Sandoz number two player in local generics market and provides operational hub for entire Nordic region
01-Jul-2004
With net sales of EUR25 million in 2003, Durascan has a broad portfolio of generic medicines that provide growth opportunities for Sandoz throughout the Nordic region. In addition, Durascan provides Sandoz with state-of-the-art quality assurance and logistics facilities, making it an attractive operational platform to fuel regional growth.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.